Arcus Biosciences, Inc.
RCUS Real Time Price USDRecent trades of RCUS by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in RCUS holdings by institutional investors
Quarterly net insider trading by RCUS's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
RCUS Estimated quarterly lobbying spending
RCUS Revenue by Segment or Geography
New RCUS patent grants
-
Patent Title: Modulators of 5′-nucleotidase, ecto and the use thereof Nov. 04, 2025
-
Patent Title: Treatment of oncogene-driven cancers Oct. 28, 2025
-
Patent Title: Parenterally administered immune enhancing drugs Oct. 07, 2025
-
Patent Title: Antibodies to tigit Sep. 16, 2025
-
Patent Title: 2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds Sep. 09, 2025
-
Patent Title: Thiazole compounds and methods of use thereof Aug. 12, 2025
-
Patent Title: Treatment of cancer utilizing an identified adenosine fingerprint May. 27, 2025
-
Patent Title: Crystalline forms of a cd73 inhibitor and uses thereof Apr. 22, 2025
-
Patent Title: Inhibitors of arg1 and/or arg2 Feb. 18, 2025
-
Patent Title: Compounds as inhibitors of axl Jan. 14, 2025
-
Patent Title: Azolopyrimidine for the treatment of cancer-related disorders Jan. 14, 2025
-
Patent Title: Inhibitors of adenosine 5′-nucleotidase Dec. 17, 2024
-
Patent Title: Process for preparing tetralin compounds Nov. 19, 2024
-
Patent Title: Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha Oct. 01, 2024
-
Patent Title: Inhibitors of hif-2α and methods of use thereof Aug. 27, 2024
-
Patent Title: Pyridone a2r antagonists Aug. 20, 2024
-
Patent Title: Arginase inhibitors Aug. 06, 2024
-
Patent Title: Solid forms of an azolopyrimidine compound May. 28, 2024
-
Patent Title: Anti-cd39 antibodies and use thereof Apr. 30, 2024
-
Patent Title: Cd73 inhibitors Mar. 19, 2024
-
Patent Title: Antibodies to tigit Nov. 21, 2023
-
Patent Title: Solid forms of a cd73 inhibitor and the use thereof Nov. 21, 2023
-
Patent Title: Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha Oct. 17, 2023
-
Patent Title: Modulators of 5′-nucleotidase, ecto and the use thereof Jun. 06, 2023
-
Patent Title: Crystalline forms of a cd73 inhibitor and uses thereof May. 16, 2023
-
Patent Title: Oral formulations of cd73 compounds Apr. 25, 2023
-
Patent Title: Dosing with an azolopyrimidine compound Oct. 25, 2022
-
Patent Title: Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2α Aug. 09, 2022
-
Patent Title: Inhibitors of cd73-mediated immunosuppression Mar. 08, 2022
-
Patent Title: Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders Jan. 11, 2022
-
Patent Title: Inhibitors of adenosine 5′-nucleotidase Jul. 13, 2021
-
Patent Title: Quinazoline-pyridine derivatives for the treatment of cancer-related disorders Jun. 29, 2021
-
Patent Title: Modulators of 5′-nucleotidase, ecto and the use thereof May. 11, 2021
-
Patent Title: Modulators of 5′-nucleotidase, ecto and the use thereof Apr. 20, 2021
-
Patent Title: Azolopyrimidine for the treatment of cancer-related disorders Sep. 03, 2019
-
Patent Title: Modulators of 5′-nucleotidase, ecto and the use thereof Mar. 26, 2019
Federal grants, loans, and purchases
Estimated quarterly amount awarded to RCUS from public contracts
Recent insights relating to RCUS
Recent picks made for RCUS stock on CNBC
ETFs with the largest estimated holdings in RCUS
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $RCUS stock a Buy, Sell, or Hold?
- What is the price target for $RCUS stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $RCUS stock?
- Who owns the most shares of $RCUS stock?
- What funds own $RCUS stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view RCUS Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
- Address Hayward, CA
- Market Cap 2.7 billion
- Employees 674
- Industrial Classification Pharmaceutical Preparations